7 completed, 5 terminated, 3 unknown, 2 recruiting. 18 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 7, Terminated 5, Unknown 3, Recruiting 2, Withdrawn 1 |
| Phase 2 | 5 | Completed 2, Unknown 2, Terminated 1 |
Follow Convalescent Plasma: new trials by email Literature Review of Convalescent Plasma trials Research Report on Convalescent Plasma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VA CoronavirUs Research and Efficacy Studies-1 Convalescent Plasma, Masked Saline Placebo - COVID-19 | Phase 3 | Terminated | VA Office of Research and Development | 75 | 2020-11-16 | 2022-09-23 |
| Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study) ConvP, FFP - Covid19 | Phase 3 | Terminated | Erasmus Medical Center | 420 | 2020-10-12 | 2022-04-01 |
| Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19 convalescent plasma - COVID-19 | Phase 2 / Phase 3 | Unknown | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 410 | 2020-08-25 | 2020-08-26 |
| Convalescent Plasma in Outpatients With COVID-19 Convalescent Plasma, Saline - Covid19 | Phase 3 | Completed | Stanford University | 511 | 2020-08-11 | 2021-10-19 |
| COVID-19 Convalescent Plasma Therapy Convalescent plasma - SARS-CoV-2 Infection, COVID-19 Infection | Phase 2 / Phase 3 | Completed | Universidad Nacional de Asunción | 350 | 2020-08-10 | 2021-03-02 |
| Convalescent Plasma for Severe COVID-19 Patients Convalescent Plasma, Best Supportive Care - Covid19 | Phase 3 | Completed | Hospital de Clinicas de Porto Alegre | 160 | 2020-07-16 | 2021-02-09 |
| Efficacy of Convalescent Plasma Therapy in Patients With COVID-19 Convalescent Plasma, Standard of Care - COVID | Phase 3 | Completed | Institute of Liver and Biliary Sciences, India | 400 | 2020-06-14 | 2021-10-14 |
| Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19) Convalescent plasma - SARS-Cov-2 | Phase 3 | Unknown | Hospital San Vicente Fundación | 231 | 2020-06-01 | 2020-05-20 |
| Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome Convalescent plasma, Standard of care - COVID, Acute Respiratory Distress Syndrome | Phase 2 / Phase 3 | Unknown | Universitas Indonesia | 60 | 2020-05-18 | 2020-08-18 |
| Phase 3 Open-Label Controlled Trial of Convalescent Plasma in Early COVID-19 Infection Convalescent Plasma, Standard of Care - Covid19 | Phase 3 | Withdrawn | Larkin Community Hospital | 2020-05-12 | 2023-10-16 | |
| Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia Convalescent anti-SARS-CoV-2 plasma, Infusion placebo - COVID, Corona Virus Infection | Phase 3 | Terminated | Thomas Benfield | 147 | 2020-05-01 | 2022-08-04 |
| Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt Convalescent Plasma - Convalescent Plasma, Covid19 | Phase 3 | Completed | Ministry of Health and Population, Egypt | 102 | 2020-04-23 | 2021-03-25 |
| Convalescent Plasma Collection and Treatment in Pediatrics and Adults Convalescent Plasma - COVID19, Coronavirus Infection | Phase 3 | Completed | West Virginia University | 117 | 2020-04-16 | 2026-05-29 |
| Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study) Convalescent plasma - COVID-19 | Phase 2 / Phase 3 | Terminated | Erasmus Medical Center | 86 | 2020-04-08 | 2022-04-01 |
| Randomised Evaluation of COVID-19 Therapy Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine - Pneumonia | Phase 3 | Recruiting | University of Oxford | 70000 | 2020-03-19 | 2026-04-21 |
| CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) Convalescent plasma - COVID-19 | Phase 3 | Terminated | Hamilton Health Sciences Corporation | 940 | 2020-03-14 | 2022-03-03 |
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam - Community-acquired Pneumonia, Influenza, COVID-19 | Phase 3 | Recruiting | UMC Utrecht | 20000 | 2016-04-11 | 2024-07-12 |
| Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea Convalescent Plasma - Hemorrhagic Fever, Ebola | Phase 2 / Phase 3 | Completed | Institute of Tropical Medicine, Belgium | 606 | 2015-02-01 | 2019-07-22 |
COVID-19 (14) · Coronavirus Infections (3) · Pneumonia (3) · Community-Acquired Pneumonia (2) · Hemorrhagic Fever, Ebola (1) · Influenza, Human (1) · Lung Diseases (1) · Pneumonia, Viral (1) · RNA Virus Infections (1) · Respiratory Distress Syndrome (1) · Respiratory Insufficiency (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1) · Virus Diseases (1)
Erasmus Medical Center (2) · Hamilton Health Sciences Corporation (1) · Hospital San Vicente Fundación (1) · Hospital de Clinicas de Porto Alegre (1) · Institute of Liver and Biliary Sciences, India (1) · Institute of Tropical Medicine, Belgium (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1) · Larkin Community Hospital (1) · Ministry of Health and Population, Egypt (1) · Stanford University (1) · Thomas Benfield (1) · UMC Utrecht (1) · Universidad Nacional de Asunción (1) · Universitas Indonesia (1) · University of Oxford (1)
United States (6) · Netherlands (4) · India (3) · Belgium (2) · Brazil (2) · Canada (2) · Colombia (2) · Estonia (2) · France (2) · Indonesia (2) · Italy (2) · Nepal (2) · Portugal (2) · Romania (2) · Spain (2)
Bart Rijnders, MD, PhD (2) · Alexandre P Zavascki, PhD (1) · Andri MT Lubis, MD, PhD (1) · Angelica Jimenez de Samudio, MD,MSc (1) · Brian Peppers, DO, PhD (1) · Clara Clausen, MD (1) · Clifton W Callaway, MD, PhD (1) · Colin McArthur, Dr (1) · Derek Angus, Prof (1) · Donald M Arnold, MD (1) · Edward N. Janoff, MD (1) · Frederick Korley, MD, PhD (1) · Johan van Griensven, MD (1) · John Marshall, Prof (1) · Juan G Sierra-Madero, MD (1)
PMID 33394942, PMID 34013969, PMID 34473343, PMID 36734509, PMID 37162745, PMID 37489818, PMID 26735992, PMID 26768570, PMID 27959686, PMID 32202722, PMID 32267771, PMID 32678530, PMID 32876697, PMID 33031652, PMID 33031764, PMID 33044747, PMID 33509275, PMID 33545096, PMID 33631065, PMID 33933206, PMID 33947446, PMID 34000257, PMID 34251506, PMID 34351721, PMID 34351722, PMID 34407339, PMID 34504336, PMID 34606578, PMID 34658014, PMID 34672950, PMID 34800427, PMID 35151397, PMID 35229691, PMID 35315874, PMID 35387813, PMID 35546145, PMID 35695334, PMID 35713300, PMID 35908569, PMID 36180450, PMID 36522698, PMID 36942550, PMID 36967714, PMID 37039790, PMID 37060915, PMID 37560085, PMID 37865101, PMID 37877585, PMID 37888913, PMID 38272046
1OT2HL156812-01 (1), 2015 (1), 2023 (1)